Expands commercial offering to 15 clinically actionable biomarker tests, including key validated alterations listed in the NCCN Guidelines® for metastatic melanoma and colorectal cancer
Target Selector™ kits are research-use-only (RUO) and designed to enable laboratories around the world to leverage Biocept's patented assay technology to perform cutting-edge liquid biopsy testing SAN DIEGO , Jan. 28, 2019 /PRNewswire/ -- Biocept, Inc.
New test uses patient's blood sample to profile and monitor for PD-L1 expression, an important biomarker in immuno-oncology treatment decision makingTest developed in collaboration with renowned pathologist David Rimm, MD, PhD, of Yale University School of Medicine
New test uses patient's blood sample to detect KRAS, predictive biomarker for solid tumor cancers SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today
New test provides physicians with a liquid biopsy option to reach informed treatment decisions for patients with melanoma and other tumors SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the
Biocept continues to expand and perform COVID-19 testing services using Thermo Fisher Scientific platform SAN DIEGO --(BUSINESS WIRE)--Nov. 22, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, now offers a single test that can detect
SAN DIEGO , April 28, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company specializing in oncology biomarker detection and monitoring through circulating tumor cells (CTCs) and cell-free circulating tumor DNA, today announced the launch of its clinical research
Introduction of blood-based assay to detect androgen receptor expression builds on leading position in detecting and monitoring cancer through liquid biopsy
SAN DIEGO --(BUSINESS WIRE)--Jun. 28, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will be added to the Russell Microcap Index after the U.S. market opens today, June 28, 2021 .
